Speaking to CNA, Ehrhart said that she has been working on the bill for nearly two years, and that it was “not a knee-jerk reaction to anything that’s currently in the media,” but that she considers it “timely.”
Ehrhart said the aim of the bill was to curb the “dangerous tide” of the increasing number of minor children identifying as transgender and being placed on drugs that delay puberty and on cross-sex hormones.
Studies have found that without puberty-blocking drugs, which delay the production of certain hormones and effectively halt a person’s sexual development, as many as 90% of children who identify as transgender eventually resume identifying as their natal sex. A study in the Netherlands from 2010 found that when a child is given hormone blockers, they almost never revert to identifying as their biological gender.
Risks of puberty blockers include reduced bone density, infertility, and disruptions to brain development. Their use for the treatment of gender dysphoria is considered to be “off-label” and has not been approved by the Food and Drug Administration.
Ehrhart said that the number of children who are seeking to change gender is an “epidemic” that is “really sweeping the country right now.” While solid data concerning the number transgender children in the United States is not available, the number of gender clinics in the country that treat pediatric patients has increased from zero in 2006 to more than 40 in 2018.
In the United Kingdom, where there is one gender clinic for pediatrics, Tavistock GIDS, the number of patients has grown exponentially over the last decade. In 2009-2010, there were 32 girls and 40 boys treated at the clinic. In 2018-2019, that figure had grown to 624 boys and 1,740 girls. A full 20% of these patients were under the age of 12, with a total of 52 aged six or below.